

* *	***************************************	* *
*	Thyroid hormones lost 5	*
が米	rigition normonics lett.s	が ※
*		*
⋇	• Which of the following hormones is not a pentide or	⋇
*	a protein in nature:	*
彩火	a protein in nature.	彩火
<b>示</b> ※		<b>示</b> ※
*	•Un eloculio	*
⋇		⋇
*		*
*	• Answer: A	*
が ※	• All of the following are entitly roid drugs. EVCEDT.	が ※
*	• All of the following are antitury on urugs, EACEPT.	*
⋇	• A. Iouiue. • P. Dropylthiouracil	*
*	• D. Propyrumouracii.	*
*	<ul> <li>C. Propranoioi.</li> <li>D. Padiaactiva iadida</li> </ul>	*
ド	• D. Radioactive iouide.	ド
<b>※</b>	• E. Carbinazoie.	<b>※</b>
⋇	• Answer: C	⋇
⋇	a T2 different rame T4 in all af the following FVCEDT.	*
米	• 13 differs from 14 in all of the following, EXCEPT:	*
ボン	• A. Duration of action.	ボン
<b>~</b> 米	• B. Potency.	<b>~</b> ※
*	• C. Origin.	*
*	• D. Protein binding.	⋇
*	• E. Iviechanism of action.	*
米米	• Answer: E	米米
<b>示</b> ※		
*		*
*		⋇
*	************************	*

** *	***************************************	* *
***	<ul> <li>Regarding the steps involved in Synthesis of thyroid hormones which</li> </ul>	***
*	is false:	*
*	• A. T4 and T3 are released into the circulation.	⋇
⋇	• B. lodide is taken up at the a basolateral cell	⋇
*	membrane	⋇
*	• C T/ and T3 are released into the Golgi hodies	※ ※
*	<ul> <li>C. 14 and 15 are released into the doigi bodies.</li> <li>D. Polynontido chains of a (thyroglobulin) are</li> </ul>	※ ※
が	• D. Polypeptide chains of g (thyrogrobulin) are	デ
<b>※</b>	synthesized in the rough	<b>示</b> ※
*	endoplasmic reticulum.	六 ※
*	• E. Newly formed To is transported to the cell surface	*
*	in small apical	⋇
*	vesicles.	⋇
*	• Answer: C	*
*	·	※ ※
彩	More than 60% of endocrinologist use this in case of	彩
<b>※</b>	hyperthyroidism, and it considered the	<b>デ</b>
不 ※	best treatment in this case:	不 ※
*	•Thionamide	※ ※
*	• Iodide	⋇
*	• radio active iodine	⋇
*	•Lithium carbonate	*
*		※ ※
が シ	Allswell, C	デ ン
*		<b>不</b> ※
*		六 ※
*		*
*		⋇
*		∦
*		*
*		*
ボボ	`*****************************	ボ

*** *	***************************************	* *
* * *	<ul> <li>which of the following is Propylthiouracil effect:</li> <li>Wolff-chaikoff effect</li> </ul>	***
<b>示</b> ※	• inhibition of peroxidase enzyme in addition to	
*	decrease peripheral deiodination of T4	*
*	•Activate releasing of T4.T3	*
*	•increase peripheral deiodination	*
*	Answer: R	*
*		彩火
不 ※		
*	Parathyroid normones (lect.6)	、 ※
*		*
*	• Hypoparathyroidism is best treated by administration	*
*	of:	* *
*	• A. Octreotide.	が ※
*	• B. Cortisone.	小 ※
*	• C. Recombinant human parathyroid hormone.	*
*	• D Spiropolactone	*
*	• F. Vitamin D	*
*	• Answer: F	※ 火
*		が ※
*	Hyperparathyroidism is best treated by:	小 ※
*	• A Prodpisolono	*
*	• R. Vitamin D	*
*	• D. Vitalilli D.	*
<b>※</b> 火	C. Calcitonini.	彩火
<b>ネ</b>	• D. Cillacalcet (calcillinetic ulug).	
*	• E. Surgery.	*
*	AIISWELLE	*
*		*
*		※ ※
<b>水</b> 米米:	<del>,</del> ************************************	が ※

**************************************	*****
*	*
• Calcitonin:	*
<ul><li>✤ A. Is effective orally.</li></ul>	*
<ul> <li>B. Is produced in the parathyroid gland.</li> </ul>	*
<ul><li>✤ C. Is a steroid hormone.</li></ul>	*
• D. Is used to control hypercalcemia.	*
• E. Increases the rate of bone turnover.	*
Answer: D	米
	デン
<ul> <li>Prug of of the choice to treat paget's disease:</li> </ul>	
• Diug of of the choice to treat paget's disease.	*
	*
♦ VIT. D	*
* • PIH	*
✤ Answer: A	*
*	*
<ul> <li>Not used in hypocalcemia in case of pseudo</li> </ul>	米
hypopituitarism:	デン
<pre></pre>	
✤ •Ca gluconate oral	*
✤ •Ca gluconate iv	*
✤ •Ca chloride	*
* Answer: A	*
*	*
*	*
* • CAMP IS used to test:	*
<ul> <li>Thyroid gland</li> <li>Y</li> </ul>	ドシ
• parathyroid gland	
•pancreas	不 ※
Answer: B	*
*	*
*	*
*	*
*****	****

**************************************	**************************************
* Deperatio	***
* Pancreatic	normones *
* (lect.	7+8) *
<ul> <li>Which of the following is N</li> <li>insulin:</li> <li>A. Insulin resistance.</li> <li>B. itching, redness, swelling</li> <li>C. Hyperglycemia.</li> <li>D. Nausea, hungry, tachyca</li> <li>E. Lipodystrophy.</li> <li>Answer: C</li> </ul>	OT an adverse reaction of g, anaphylaxis shock. wrdia. ***************
<ul> <li>The following is short-acting iven S.C and I.V:</li> <li>A. Protamine zinc suspensi</li> <li>B. Isophane zinc suspensio</li> <li>C. Extended insulin zinc suspension.</li> <li>D. Insulin zinc suspension.</li> <li>E. Regular insulin.</li> <li>Answer: E</li> </ul>	ag insulin that could be ** on. ** n. ** spension. ** ** **
<ul> <li>The following insulin is wid</li> <li>A. Insulin zinc suspension.</li> <li>B. Protamine zinc suspensi</li> <li>C. Insulin lispro.</li> <li>D. Regular insulin.</li> <li>E. Isophane zinc suspension</li> <li>Answer: C</li> <li>**</li> </ul>	ely used in insulin pumps: ** on. ** n. ** ****************************

***	****	ĸ
*	>	K
*		が
<b>※</b>	• Ketoacidosis is best managed by administration of:	ドレ
<b>※</b>	• A. Insulin lispro.	マド
*	B Insulin zinc suspension	これ
*	• C Regular insulin	K
*	• D. Insulin glargine	K
*	• E. Rogular insulin + K+	*
*		がレ
デ 火	Allswell, E	ドレ
<b>ネ</b>	· Diabatas incinidus is a major side offect to:	マボ
*	• Diabetes insipidus is a major side effect to:	*
*	• A. Bromocriptine.	K
*	• B. Desmopressin.	K
*	• C. Growth hormone.	ドレ
彩火	• D. Lithium carbonate.	ドレ
不 ※	• E. Dexamethasone.	アド
*	• Answer: D	<b>下</b> 、 、
*	>	ĸ
⋇	<ul> <li>Regarding sulfonylurea oral hypoglycemic agents,</li> </ul>	K
*	choose the wrong	が
*	statement:	ドレ
ネ	• A. Hypoglycaemia as a side effect to such class of	マド
*	antidiabetic agents	アド
*	is not frequent.	*
*	• B. As compared to first generation, second	K
*	generation sulfonylureas	*
*	are less potent.	が
<b>ネ</b>	• C. Their actions are mediated by interacting with	アド
不 ※	specific receptors.	アド
*		*
*	>	K
***	***************************************	ĸ

*** *	**************************************	÷ ₹
***	<ul> <li>D. They strongly bind plasma albumin (drug-drug</li> <li>interactions are</li> <li>common)</li> </ul>	$\epsilon \epsilon \epsilon$
** **	<ul> <li>E. They increase pancreatic insulin release and</li> <li>increase insulin affinity</li> </ul>	てそそ
* *	to its peripheral receptors.	< < < <
** **	• All the following are the Chronic complications of	さそそ
* *	Diabetes mellitus	€ € ¢
* * *	<ul> <li>A. Strokes.</li> <li>B. Coronary heart disease.</li> </ul>	í í f
* *	<ul> <li>C. Renal failure.</li> <li>D. Diabetic ketoacidosis.</li> </ul>	$\epsilon$
* * *	<ul> <li>E. Poor wound healing.</li> <li>Answer: D</li> </ul>	÷ ÷ ÷
**	<ul> <li>All the following are the Pharmacological actions of</li> </ul>	<b>{ { { } }</b>
* * *	insulin EXCEPT:     *       • A. Inhibit lipolysis.     *	í í í
**	<ul> <li>B. Diminish hepatic glycogenolysis.</li> <li>C. Inhibit hepatic gluconeogenesis.</li> </ul>	* * *
* * *	<ul> <li>D. Induction of gluconeogenesis.</li> <li>E. Promote hepatic glucose storage into glycogen.</li> </ul>	t t t t
**	• Answer: D	· · · · · · · · · · · · · · · · · · ·
** ** **		さそそ
**	***************************************	÷

** *	***************************************	* *
***	• All the following are mechanisms of action of the sulfonylureas	***
<b>***</b> **	• A. Increase insulin receptor number and the affinity to insulin.	<b>~※※</b> ×
<b>***</b> **	<ul> <li>B. Ameliorating insulin resistance.</li> <li>C. Direct stimulation of insulin release from the paneroatic B-colls.</li> </ul>	
<b>**</b> ***	<ul> <li>D. Inhibition of glucagon secretion by pancreas alpha cells.</li> </ul>	
****	<ul> <li>E. Induction of glucagon secretion by pancreas.</li> <li>Answer: E</li> </ul>	***
**	<ul> <li>Sitagliptin is an example of:</li> <li>A. A synthetic prostaglandin</li> </ul>	***
***	<ul> <li>B. An inhibitor to incretin metabolism</li> <li>C. An ultra short-acting insulin</li> </ul>	***
* * *	<ul> <li>D. An antihistamine</li> <li>E. A serotonin agonist</li> <li>Answer: B</li> </ul>	***
* * *	• A 45 year old diabetic female patient who is on 100	***
***	units of insulin daily, was found to have normal blood levels of C-	***
· * * * *	<ul> <li>Peptide. Normal</li> <li>levels of C-peptide in her blood indicate that she:</li> <li>A. Is taking also an oral hypoglycemic agent.</li> </ul>	
<b>**</b> **	• B. Has normal pancreatic function.	<b>※※</b> ※
* **	<del>;</del> *******************	※ ※

*** *	***************************************	**
*	• C. Has type I diabetes mollitus	*
*	• C. Has type I diabetes menitus.	*
*	• D. Is taking too much insulin.	*
*	• E. Is taking numan insulin.	※ *
77 	• Answer: B	行
		<b>~</b> ※
*	• All of the following are true statements about the	*
*	thiazolidinediones	*
*	EXCEPT	*
*	• A. Thiazolidinediones may be hepatotoxic in some	*
*	individuals.	※ 火
*	• B. Thiazolidinediones increase the number of insulin	が ※
*	receptors on the	う ※
*	cell membrane surface.	*
*	• C. Thiazolidinediones bind a nuclear receptor in	*
*	tissue termed PPAR-y.	*
*	• D. Thiazolidinediones are a novel class of drugs that	*
*	were initially	※ 火
<b>ネ</b> ※	identified for their insulin- sensitizing properties.	<b>六</b> ※
*	• F All of the above	へ ※
*	• Answer: h	*
⋇		*
*	• The main problem of metformin is that :	*
*	• A It increases the risk of lactic acidesis	*
*	• A. It increases the risk of katascidosis	ざた
	• D. It increases the fisk of ketoaciuosis.	<b>~</b> ※
*	• C. It causes development of congestive heart failure.	*
*	• D. It causes hypoglycemia.	*
*	• E. All of the above.	*
*	• Answer: A	*
*		※ 火
<b>水</b> 米米	, ************************************	う い い
	(x, x) (x, y)	

** * *	**************************************	***
*	• Uupoglucomia rarolu coon with those drugs when	K
*	• Typogrycenna rareiy seen with these drugs when	K
*	Used as	が
彩	monotherapy EXCEPT:	ドレ
ボ	• A. Metformin.	ドレ
<b>示</b> <u>火</u>	• B. Acarbose.	ア に
*	• C. Miglitol.	マズ
*	• D. Glyburide.	к К
*	• F. All of the above.	K
*	• Answer: d	K
*		K
*	• In addition to its offects on stimulating glucose	K
*	• In addition to its effects on stimulating glucose	K
*	uptake by tissues,	が
*	insulin has other physiological actions including:	ドレ
717 	• A. Increase hepatic glycogenolysis.	マア
不 ※	<ul> <li>B. Decreasing hepatic glucose storage into glycogen.</li> </ul>	マン
*	C. Promoting hepatic gluconeogenesis.	てい
*	• D. Inhibit lipolysis.	K
*	• E. All of the above.	Ķ
*	• Answer: d	K
*		K
*	• Sulfonvluros recentor in B cell membrane activation	K
*		K
*	results in:	が
*	• A. ATP-sensitive K+-channel activation.	ドレ
77 	B. Cellular membrane depolarization.	ド に
*	<ul> <li>C. Ca2+ removal from the cell via voltage-dependent</li> </ul>	マズ
*	Ca2+ channel.	ズ
*	• D. Glucose release.	X
*		K
*	⇒	Ķ
***	***************************************	K

**	*****	****
不 ※		
*	• E. All of the above.	*
*	• Answer: b	⋇
*		*
*	<ul> <li>Treatment of Type 2 Diabetes include:</li> </ul>	*
*	<ul> <li>A. Agents which decrease insulin secretion.</li> </ul>	*
*	• B. Agents which decrease the sensitivity of target	ポ
717 	organs to insulin.	77 _\_
*	• C. Agents which increase glucose absorption.	
*	• D. Insulin.	*
*	• F All of the above	⋇
*	• Answer: d	*
*	Answer. d	*
*		*
が ×		ネシ
*	FULLOWING IS USED TO ASSES	
*	BETA CELLS FUNCTION IN A DIABETIC PATIENT	
*	RECEIVING 100 UNITS OF INSULIN	*
*	ZINC SUSPENSION?	*
*	•C-peptide	*
*		*
*	<ul> <li>Metformin side effect:</li> </ul>	*
が 上	<ul> <li>decrease B12 absorption</li> </ul>	ネシ
<b>※</b>	•Alkalosis	
*	<ul> <li>constipation</li> </ul>	*
*	Answer:A	*
⋇		*
*		*
*		*
<b>※</b>		*
<b>ド</b>		术 火
<b>~</b> ※		
**	*****	****

** *	**************************************	<b>※</b> ※
*	a) M/biab af the following is Mismatched.	*
✵	• which of the following is ivilsmatched:	米
✵	•Buformin → increase glycolysis	彩
*	• sitagliptin $\rightarrow$ GLP-1 agonist	*
*	• Migliol $\rightarrow$ decrease carbs absorption	米
*	Answer: B	*
*		彩
ボ	Most important side effect off insulin is:	ジン
77 _\	hypoglycemia	行火
		之
不 ※		う ※
*	• Allergy	<b>※</b>
*	Answer: A	米
*	>	· ※
⋇	•An example of Peakless insulin:	米
*	•Humulin	彩
*	• insulin glargine	*
*	•Ultralente	米
*	Answer: B	彩
彩		ジン
が	a) A/hat ia tha NAOA af Culfamulumaaa	行火
<b>示</b> 火	• what is the work of Sulfonylureas:	之
不 ※	• decrease no. of B cells	う
*	•increase gluconeogenesis	<b>※</b>
*	increases insulin release	<b>※</b>
*	Answer: C	※
⅔	<del>}</del>	彩
*	<del>}</del>	彩
*	<del>}</del>	*
*		米
*		彩
ボ		ジン
77 X	7	うと
**	**************************************	之